奥沙利铂联合卡培他滨方案治疗晚期胃癌的临床观察

The Clinical Observation of Oxaliplatin in Combination with Capecitabine in Patients with Advanced Gastric Cancer

目的观察奥沙利铂联合卡培他滨方案治疗晚期胃癌的近期疗效及安全性。方法对29例晚期胃癌患者采用奥沙利铂85 mg/m^2,静脉滴注,第1天;卡培他滨2500 mg/m^2/d分早晚2次餐后口服,第1-14天,每3周重复,连用2个周期以上。按照WHO实体肿瘤近期客观疗效评定标准进行评价。结果全组29例病例均可评价疗效。其中CR 2例（6.89%）,PR 9例（31.03%）,SD 11例（37.93%）,PD 7例（24.14%）,总有效率为37.92%。主要不良反应为中性粒细胞减少、手足综合征、恶心呕吐、腹泻等,均可逆,无治疗相关死亡。结论奥沙利铂联合卡培他滨方案二线治疗晚期胃癌,疗效肯定,耐受性良好,值得进一步研究。

Objective To observe the efficacy and safety of Oxaliplatin in combination with capecitabine in treating advanced gastric cancer. Methods Twenty nine patients with advanced gastric cancer received chemotherapy ： Oxalip latin 85 mg/m^2 i. v, The first day ; combining oral capecitabine 2500 mg/m^2 （ used in the morning and evening, respectively）, from the first day to the fourteenth day;and repeated every 3 weeks. The efficacy and safety were assessed in every cycle. Results 2 cases（6. 89% ）achieved CR,9 cases（31.03% ）had PR, 11 cases（37.93% ）had SD,7 cases （24. 14% ）had PD,with an overall response rate of 37.92%. The most common adverse effects were leucopenia, hand-foot syndrome, nausea, vomiting and diarrhea. There was no treatment-related death. Conclusion Chemotherapy with oxaliplatin combined with capecitabine is effective and well to lerated to the patients with advanced gastric cancer.